行情

ADXS

ADXS

Advaxis
NASDAQ

实时行情|Nasdaq Last Sale

0.3046
-0.0314
-9.34%
交易中 14:55 10/14 EDT
开盘
0.3200
昨收
0.3360
最高
0.3305
最低
0.3012
成交量
597.47万
成交额
--
52周最高
11.82
52周最低
0.2051
市值
752.67万
市盈率(TTM)
-0.0706
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADXS 新闻

  • 9 Healthcare Stocks Moving In Monday's Pre-Market Session
  • Benzinga.7小时前
  • 28 Healthcare Stocks Moving In Friday's Pre-Market Session
  • Benzinga.3天前
  • Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research
  • Business Wire.4天前
  • Advaxis Reports Collaboration With UCLA For Glioblastoma Immunotherapy Discovery Research
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
+0.44%
制药与医学研究
+0.16%

热门股票

名称
价格
涨跌幅

ADXS 简况

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
展开

Webull提供Advaxis, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。